| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/07/2005 | CN1217584C Effervescent green tea extract formulation |
| 09/06/2005 | US6939946 Ring modified cyclic peptide analogs |
| 09/06/2005 | US6939937 Mold inhibitor integrated within a matrix and method of making same |
| 09/06/2005 | US6939865 Cardiovascular disorders; antiarrhythmia agents |
| 09/06/2005 | US6939846 Use of a polypeptide for treatment of pruritis in animals |
| 09/06/2005 | US6939569 Medical device having anti-infective and contraceptive properties |
| 09/06/2005 | US6939568 Hydrated dressing containing metal microbiocide |
| 09/06/2005 | US6939564 core of the supramolecular assembly, whereas the shell consists of uncharged hydrophilic polymers; inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability |
| 09/06/2005 | US6939562 Collagen/polysaccharide bilayer matrix |
| 09/06/2005 | US6939561 Methods and compositions for polyene antibiotics with reduced toxicity |
| 09/06/2005 | US6939560 Pharmaceutical composition having two coating layers |
| 09/06/2005 | US6939559 Pharmaceutical composition for application to mucosa |
| 09/06/2005 | US6939558 intravaginal devices containing progesterone that can be used as an estrus inductor in an organism, such as bovine, swine, equine |
| 09/06/2005 | US6939557 biocompatible therapeutic article comprising, a macromer having polymerized end groups, precipitated human growth hormone, and a molecule or mixture of molecules which preferentially excludes proteins |
| 09/06/2005 | US6939556 Minimally compliant, volume efficient piston for osmotic drug delivery systems |
| 09/06/2005 | US6939550 Storage stability |
| 09/06/2005 | US6939546 Model for testing immunogenicity of peptides |
| 09/06/2005 | US6939542 Contacting vitreous humor with beta-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase, and/or protein kinase; thimerosal-free |
| 09/06/2005 | US6939538 Extended release analgesic for pain control |
| 09/06/2005 | US6939534 Method to treat pulmonary hypoplasia in the newborn |
| 09/06/2005 | US6939530 Preparation of further diagnostic agents |
| 09/06/2005 | US6939376 Drug-delivery endovascular stent and method for treating restenosis |
| 09/06/2005 | US6939033 static mixer combines a first phase of an active agent and a polymer, with a second phase to form an emulsion |
| 09/06/2005 | CA2278025C Aqueous suspension for nasal administration |
| 09/06/2005 | CA2267760C Stent lining |
| 09/06/2005 | CA2179778C Deuterised active agents in transdermal application |
| 09/06/2005 | CA2119516C Ointment for wound treatment |
| 09/06/2005 | CA2105652C Reducing wound scarring with antibodies to growth factors |
| 09/04/2005 | CA2491341A1 Topical formulations for treatment of rosacea |
| 09/01/2005 | WO2005080433A2 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
| 09/01/2005 | WO2005080410A1 Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders |
| 09/01/2005 | WO2005080032A1 Process for producing iron colloid, and iron-colloid-bearing polymer micelle |
| 09/01/2005 | WO2005079970A1 Process for production of ionically crosslinked polysaccharide microspheres |
| 09/01/2005 | WO2005079968A1 Storage stable multi-microcapsules having adjustable synergitically active functional content components |
| 09/01/2005 | WO2005079879A1 Collagen gel and process for producing the same |
| 09/01/2005 | WO2005079860A1 New complexes |
| 09/01/2005 | WO2005079858A1 Stable, palatable syrup containing ibuprofen and method of its preparation |
| 09/01/2005 | WO2005079856A1 Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules |
| 09/01/2005 | WO2005079855A1 Saccharose-fatty- acid-based pentetration promoter |
| 09/01/2005 | WO2005079854A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| 09/01/2005 | WO2005079853A2 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 09/01/2005 | WO2005079841A2 Gm1 binding deficient exotoxins for use as immunoadjuvants |
| 09/01/2005 | WO2005079820A1 Immunopotentiator |
| 09/01/2005 | WO2005079818A1 Glycerol solution containing dissolved ozone, solidified glycerol containing dissolved ozone, mixed solution containing dissolved ozone, process for producing glycerol solution containing dissolved ozone, process for producing mixed solution containing dissolved ozone, and method of storing glycerol solution containing diss |
| 09/01/2005 | WO2005079816A1 An anti-cancer substance of polysaccharides, its preparation method and application |
| 09/01/2005 | WO2005079811A1 Improved therapy using a combination of raloxifene and alendronate |
| 09/01/2005 | WO2005079809A1 Transparent latanoprost eye drops |
| 09/01/2005 | WO2005079794A1 Pharmaceutical compositions based on anticholinergics and pegsunercept |
| 09/01/2005 | WO2005079777A1 Solid formulations of ospemifene |
| 09/01/2005 | WO2005079768A2 Amoxicillin instant granulate |
| 09/01/2005 | WO2005079765A1 Compositions for the treatment of nail and skin disorders |
| 09/01/2005 | WO2005079764A1 Compositions and methods for timed release of water-soluble nutritional supplements |
| 09/01/2005 | WO2005079763A2 Compression-coated tablets and manufacture thereof |
| 09/01/2005 | WO2005079762A1 Multilayer tablet |
| 09/01/2005 | WO2005079761A1 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| 09/01/2005 | WO2005079760A1 Particulates |
| 09/01/2005 | WO2005079759A2 Pharmaceutical composition for oral application and method for preparing thereof |
| 09/01/2005 | WO2005079758A1 A microemulsion preparation of high concentration propofol for anesthetic uses |
| 09/01/2005 | WO2005079757A2 Therapeutic agent carrier compositions |
| 09/01/2005 | WO2005079756A2 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| 09/01/2005 | WO2005079755A2 Interleukin-13 antagonist powders, spray-dried particles, and methods |
| 09/01/2005 | WO2005079754A2 Layered silicate nanoparticle-polymer composite medical articles |
| 09/01/2005 | WO2005079753A2 Extended release pharmaceutical compositions of divalproex sodium |
| 09/01/2005 | WO2005079752A2 Controlled release pharmaceutical compositions with improved bioavailability |
| 09/01/2005 | WO2005079751A2 Oral pharmaceutical compositions of candesartan cilexetil |
| 09/01/2005 | WO2005079750A2 Films for use as dosage forms |
| 09/01/2005 | WO2005079749A2 Chitosan containing solution |
| 09/01/2005 | WO2005079748A2 Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient |
| 09/01/2005 | WO2005079747A1 Pharmaceutical preparation for the oral cavity |
| 09/01/2005 | WO2005079704A1 Drug-enhanced adhesion prevention |
| 09/01/2005 | WO2005079703A1 Biocompatible polymeric delivery systems for sustained release of quinazolinones |
| 09/01/2005 | WO2005079603A1 Dietary fiber composition |
| 09/01/2005 | WO2005079511A2 SYSTEM IMMUNE ACTIVATION METHOD USING NON CpG NUCLEIC ACIDS |
| 09/01/2005 | WO2005079506A2 Systemic immune activation method using nucleic acid-lipid complexes |
| 09/01/2005 | WO2005079387A2 Implantable drug delivery device including wire filaments |
| 09/01/2005 | WO2005079384A2 Expandable gastric retention device |
| 09/01/2005 | WO2005079317A2 Prostate hypertrophy treatment composition and method |
| 09/01/2005 | WO2005079284A2 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 09/01/2005 | WO2005079204A2 Artificial synapse chip |
| 09/01/2005 | WO2005065682A3 Rabeprazole containing formulation |
| 09/01/2005 | WO2005065639A3 Novel pharmaceutical compositions |
| 09/01/2005 | WO2005065435A3 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 09/01/2005 | WO2005058480A3 Particle and particle manufacturing method and apparatus |
| 09/01/2005 | WO2005055949A3 Sustained release preparations composed of biocompatible complex microparticles |
| 09/01/2005 | WO2005044193A3 Product and process for increasing compactibility of carbohydrates |
| 09/01/2005 | WO2005041878A3 Compositions and methods for increasing hdl and hdl-2b levels |
| 09/01/2005 | WO2005037341A8 Small particle aerosol liposomes for delivery of anti-cancer drugs |
| 09/01/2005 | WO2004098561A3 Particulate materials |
| 09/01/2005 | US20050192647 Electrical devices and anti-scarring agents |
| 09/01/2005 | US20050192561 Infusion pump system, an infusion pump unit and an infusion pump |
| 09/01/2005 | US20050192528 Methods, apparatus and charged chemicals for control of ions, molecules or electrons |
| 09/01/2005 | US20050192434 For use as binder resins and drug delivery agents; bioavailability |
| 09/01/2005 | US20050192371 Diffusion sustained release devices; low residual solvent, high active ingredient encapsulation; produced at low operating temperature in bulk with controlled particle size and morphology |
| 09/01/2005 | US20050192358 carbocyclic imidodisulfamide compounds; preferably but not limited to infections caused by orthopox viruses |
| 09/01/2005 | US20050192340 Simvastatin formulations and methods of making same |
| 09/01/2005 | US20050192315 New compositions containing quinoline compounds |
| 09/01/2005 | US20050192308 N-but-E-enyl norbuprenorphine and methods of use |
| 09/01/2005 | US20050192274 Combinations of drugs for the treatment of neoplastic disorders |
| 09/01/2005 | US20050192260 Pharmaceutical composition |
| 09/01/2005 | US20050192259 A sustained release formulation of an aldosterone antagonist orally administered about 6-12 hours prior to the acrophase to provide a profile of plasma drug concentration corresponding to the diurnal cycle of plasma aldosterone concentration; hypotensive agents; circadi rhythm; cardiovascular disorders |